株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌および腫瘍プロファイリングの世界市場:用途(診断、個別化医療)、手法(プロテオミクス、メタボロミクス、エピジェネティクス)、技術別

Cancer/Tumor Profiling Market Analysis Report By Technology, By Application (Diagnostics, Personalized Medicine), By Technique (Proteomics, Metabolomics, Epigenetics), And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 748448
出版日 ページ情報 英文 135 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
癌および腫瘍プロファイリングの世界市場:用途(診断、個別化医療)、手法(プロテオミクス、メタボロミクス、エピジェネティクス)、技術別 Cancer/Tumor Profiling Market Analysis Report By Technology, By Application (Diagnostics, Personalized Medicine), By Technique (Proteomics, Metabolomics, Epigenetics), And Segment Forecasts, 2018 - 2025
出版日: 2018年11月02日 ページ情報: 英文 135 Pages
概要

世界の癌および腫瘍プロファイリング市場は、2018年から2025年にかけて8.8%のCAGRで推移し、2025年までに210億米ドル規模の市場に成長することが予測されています。癌検出におけるオーミクス研究の応用の拡大が当市場の成長を促進しています。

当レポートでは、世界の癌および腫瘍プロファイリング市場を調査し、市場の概要、手法・技術・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • 情報分析
  • 市場構成と検証

第2章 エグゼクティブサマリー

  • 市場のスナップショット

第3章 市場変数、動向、範囲

  • 市場区分と範囲
  • 成長見通しマッピング
  • SWOT分析
  • ファイブフォース分析

第4章 世界の癌/腫瘍プロファイリング市場:手法別

  • 市場動向の分析:手法別
  • ゲノミクス
  • プロテオミクス
  • メタボロミクス
  • エピジェネティクス

第5章 世界の癌/腫瘍プロファイリング市場:技術別

  • 市場動向の分析:技術別
  • シーケンシング
    • 次世代シーケンシング(NGS)
    • サンガーシークエンシング
    • パイロシーケンシング
  • In-Situ ハイブリダイゼーション
  • 免疫組織染色
  • 定量的PCR(qPCR)
  • マイクロアレイ

第6章 世界の癌/腫瘍プロファイリング市場:用途別

  • 市場動向の分析:用途別
  • 個別化医療
  • 診断
  • 研究
    • 癌研究
    • バイオマーカー発券

第7章 世界の癌/腫瘍プロファイリング市場:地域別

  • 市場シェアの分析:地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 戦略の枠組み
  • 参入企業のカテゴリー
    • Illumina, Inc.
    • Qiagen N.V.
    • Neogenomics Laboratories Inc.,
    • HTG Molecular Diagnostics, Inc.,
    • Genomic Health Inc.,
    • Caris Life Sciences
    • Helomics Corporation
    • NanostringTechologies
    • Oxford Gene Technology
    • Ribomed Biotechnologies, Inc.,
    • Personal Genome Diagnostics
    • GenomeDX
    • Guardant Health
    • Foundation Medicine
図表

List of Tables

  • TABLE 1 North America Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 2 North America Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 3 North America Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 4 North America Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 5 North America Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 9 U.S. Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 11 Canada Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 12 Canada Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 13 Canada Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 14 Canada Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 15 Canada Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 16 Europe Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 17 Europe Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 18 Europe Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 19 Europe Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 20 Europe Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 21 Germany Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 22 Germany Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 23 Germany Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 24 Germany Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 25 Germany Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 26 U.K. Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 27 U.K. Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 28 U.K. Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 29 U.K. Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 30 U.K. Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 31 Asia Pacific Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 32 Asia Pacific Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 33 Asia Pacific Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 34 Asia Pacific Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 35 Asia Pacific Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 36 China Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 37 China Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 38 China Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 39 China Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 40 China Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 41 Japan Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 42 Japan Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 43 Japan Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 44 Japan Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 45 Japan Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 46 Latin America Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 47 Latin America Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 48 Latin America Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 49 Latin America Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 50 Latin America Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 51 Brazil Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 52 Brazil Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 53 Brazil Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 54 Brazil Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 55 Brazil Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 56 MEA Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 57 MEA Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 58 MEA Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 59 MEA Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 60 MEA Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)
  • TABLE 61 South Africa Cancer tumor profiling market, by technique scope, 2014 - 2025 (USD Million)
  • TABLE 62 South Africa Cancer tumor profiling market, by technology scope, 2014 - 2025 (USD Million)
  • TABLE 63 South Africa Cancer tumor profiling market, by sequencing technologies, 2014 - 2025 (USD Million)
  • TABLE 64 South Africa Cancer tumor profiling market, by application, 2014 - 2025 (USD Million)
  • TABLE 65 South Africa Cancer tumor profiling market, by research, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restrain relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Cancer tumor profiling Market, Technique Type outlook key takeaways
  • FIG. 16 Cancer tumor profiling market: Technique Scope movement analysis
  • FIG. 17 Global genomics market, 2014 - 2025 (USD Million)
  • FIG. 18 Global proteomics market, 2014 - 2025 (USD Million)
  • FIG. 19 Global metabolomics market, 2014 - 2025 (USD Million)
  • FIG. 20 Global epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 21 Cancer tumor profiling market technology outlook: Key takeaways
  • FIG. 22 Cancer tumor profiling market: technology market: movement analysis
  • FIG. 23 Global sequencing technology market, 2014 - 2025 (USD Million)
  • FIG. 24 Global NGS market, 2014 - 2025 (USD Million)
  • FIG. 25 Global sanger sequencing market, 2014 - 2025 (USD Million)
  • FIG. 26 Global pyro sequencing market, 2014 - 2025 (USD Million)
  • FIG. 27 Glass in situ hybridization market, 2014 - 2025 (USD Million)
  • FIG. 28 Immunohistochemistry market, 2014 - 2025 (USD Million)
  • FIG. 29 Global qPCR market, 2014 - 2025 (USD Million)
  • FIG. 30 Global microarray market, 2014 - 2025 (USD Million)
  • FIG. 31 Cancer tumor profiling market application outlook: Key takeaways
  • FIG. 32 Cancer tumor profiling market: Application movement analysis
  • FIG. 33 Global personalized cancer medicine market, 2014 - 2025 (USD Million)
  • FIG. 34 Global oncological diagnostics market, 2014 - 2025 (USD Million)
  • FIG. 35 Global research market, 2014 - 2025 (USD Million)
  • FIG. 36 Global cancer research market, 2014 - 2025 (USD Million)
  • FIG. 37 Global biomarker discovery market, 2014 - 2025 (USD Million)
  • FIG. 38 Regional market place: Key takeaways
  • FIG. 39 Regional outlook, 2016 & 2025
  • FIG. 40 North America cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 41 U.S. cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 42 Canada cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 43 Europe cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 44 Germany cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 45 U.K. cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 46 Asia Pacific cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 47 China cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 48 Japan cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 49 Latin America cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 50 Brazil cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 51 MEA cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 52 South Africa cancer tumor profiling market, 2014 - 2025 (USD Million)
  • FIG. 53 Strategy framework
  • FIG. 54 Participant categorization
目次
Product Code: GVR-2-68038-625-7

The global cancer/tumor profiling market size is expected to reach USD 21.08 billion by 2025, exhibiting a CAGR of 8.8%, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Further key findings from the report suggest:

  • Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption. The segment is expected to fuel exhibit a CAGR of over 9.0%
  • Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
  • Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well

Key players include: Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.

Table of Contents

Chapter 1: Research Methodology

  • 1.1 Information procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation

Chapter 2: Executive Summary

  • 2.1 Market Snapshot

Chapter 3: Cancer Tumor Profiling Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Use of omics sciences in the development of personalized medicine
      • 3.1.1.2 Developing trend of PoC cancer tests
      • 3.1.1.3 Technological advancements
    • 3.1.2 Market Restrain Analysis
      • 3.1.2.1 High capital and low benefit ratio of biomarkers
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Cancer tumor profiling - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4: Cancer Tumor Profiling: Technique Type Estimates & Trend Analysis

  • 4.1 Cancer tumor profiling market: Technique Scope movement analysis
  • 4.2 Genomics
    • 4.2.1 Genomics market, 2014 - 2025 (USD Million)
  • 4.3 Proteomics
    • 4.3.1 Proteomics market, 2014 - 2025 (USD Million)
  • 4.4 Metabolomics
    • 4.4.1 Metabolomics market, 2014 - 2025 (USD Million)
  • 4.5 Epigenetics
    • 4.5.1 Epigenetics market, 2014 - 2025 (USD Million)

Chapter 5: Cancer Tumor Profiling: Technology Estimates & Trend Analysis

  • 5.1 Cancer tumor profiling market: Technology movement analysis
  • 5.2 Sequencing Technologies
    • 5.2.1 Sequencing technologies market, 2014 - 2025 (USD Million)
    • 5.2.2 Next Generation Sequencing(NGS)
      • 5.2.2.1 NGS market, 2014 - 2025 (USD Million)
    • 5.2.3 Sanger Sequencing
      • 5.2.3.1 Sanger sequencing market, 2014 - 2025 (USD Million)
    • 5.2.4 Pyro Sequencing
      • 5.2.4.1 Pyro sequencing market, 2014 - 2025 (USD Million)
  • 5.3 In Situ Hybridization
    • 5.3.1 In situ hybridization market, 2014 - 2025 (USD Million)
  • 5.4 Immunohistochemistry
    • 5.4.1 Immunohistochemistry market, 2014 - 2025 (USD Million)
  • 5.5 Quantitative PCR (qPCR)
    • 5.5.1 qPCR market, 2014 - 2025 (USD Million)
  • 5.6 Microarray
    • 5.6.1 Microarray market, 2014 - 2025 (USD Million)

Chapter 6: Cancer Tumor Profiling: Application Estimates & Trend Analysis

  • 6.1 Cancer tumor profiling market: application movement analysis
  • 6.2 Personalized Cancer Medicine
    • 6.2.1 Personalized cancer medicine market, 2014 - 2025 (USD Million)
  • 6.3 Oncological Diagnostics
    • 6.3.1 Oncological diagnostics market, 2014 - 2025 (USD Million)
  • 6.4 Research
    • 6.4.1 Research market, 2014 - 2025 (USD Million)
    • 6.4.2 Cancer research
      • 6.4.2.1 Cancer research market, 2014 - 2025 (USD Million)
    • 6.4.3 Biomarker discovery
      • 6.4.3.1 Biomarker discovery, 2014 - 2025 (USD Million)

Chapter 7: Cancer Tumor Profiling: Regional Estimates & Trend Analysis, by Application, Technique and Technology scope

  • 7.1 Cancer tumor profiling market share by region, 2016 & 2025
  • 7.2 North America
    • 7.2.1 North America Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada Cancer tumor profiling market, 2014 - 2025 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Germany Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.3.3 U.K.
      • 7.3.3.1 U.K. Cancer tumor profiling market, 2014 - 2025 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.4.3 Japan
      • 7.4.3.1 Japan Cancer tumor profiling market, 2014 - 2025 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Cancer tumor profiling market, 2014 - 2025 ( USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Cancer tumor profiling market, 2014 - 2025 (USD Million)
  • 7.6 Middle East and Africa
    • 7.6.1 Middle East and Africa Cancer tumor profiling market, 2014 - 2025 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Cancer tumor profiling market, 2014 - 2025 (USD Million)

Chapter 8: Competitive Landscape

  • 8.1 Strategy framework
  • 8.2 Market participation categorization
    • 8.2.1 Illumina, Inc.
      • 8.2.1.1 Company overview
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Strategic initiatives
    • 8.2.2 Qiagen N.V.
      • 8.2.2.1 Company overview
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Strategic initiatives
    • 8.2.3 Neogenomics Laboratories Inc.,
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 HTG Molecular Diagnostics, Inc.,
      • 8.2.4.1 Company Overview
      • 8.2.4.2 Financial Information
      • 8.2.4.3 Product Benchmarking
      • 8.2.4.4 Strategic Initiatives
    • 8.2.5 Genomic Health Inc.,
      • 8.2.5.1 Company Overview
      • 8.2.5.2 Financial Information
      • 8.2.5.3 Product Benchmarking
      • 8.2.5.4 Strategic Initiatives
    • 8.2.6 Caris Life Sciences
      • 8.2.6.1 Company Overview
      • 8.2.6.2 Financial Information
      • 8.2.6.3 Product Benchmarking
      • 8.2.6.4 Strategic Initiatives
    • 8.2.7 Helomics Corporation
      • 8.2.7.1 Company Overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product Benchmarking
      • 8.2.7.4 Strategic Initiatives
    • 8.2.8 NanostringTechologies
      • 8.2.8.1 Company Overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product Benchmarking
      • 8.2.8.4 Strategic Initiatives
    • 8.2.9 Oxford Gene Technology
      • 8.2.9.1 Company Overview
      • 8.2.9.2 Financial Performance
      • 8.2.9.3 Product Benchmarking
      • 8.2.9.4 Strategic Initiatives
    • 8.2.10 Ribomed Biotechnologies, Inc.,
      • 8.2.10.1 Company Overview
      • 8.2.10.2 Financial Performance
      • 8.2.10.3 Product Benchmarking
      • 8.2.10.4 Strategic Initiatives
    • 8.2.11 Personal Genome Diagnostics
      • 8.2.11.1 Company Overview
      • 8.2.11.2 Financial Performance
      • 8.2.11.3 Product Benchmarking
      • 8.2.11.4 Strategic Initiatives
    • 8.2.12 GenomeDX
      • 8.2.12.1 Company Overview
      • 8.2.12.2 Financial Performance
      • 8.2.12.3 Product Benchmarking
      • 8.2.12.4 Strategic Initiatives
    • 8.2.13 Guardant Health
      • 8.2.13.1 Company Overview
      • 8.2.13.2 Financial Performance
      • 8.2.13.3 Product Benchmarking
      • 8.2.13.4 Strategic Initiatives
    • 8.2.14 Foundation Medicine
      • 8.2.14.1 Company Overview
      • 8.2.14.2 Financial Performance
      • 8.2.14.3 Product Benchmarking
      • 8.2.14.4 Strategic Initiatives
Back to Top